MA43518B1 - 3-azabicyclo[3.1.0]hexanes substitués servant d'inhibiteurs de cétohexokinase - Google Patents

3-azabicyclo[3.1.0]hexanes substitués servant d'inhibiteurs de cétohexokinase

Info

Publication number
MA43518B1
MA43518B1 MA43518A MA43518A MA43518B1 MA 43518 B1 MA43518 B1 MA 43518B1 MA 43518 A MA43518 A MA 43518A MA 43518 A MA43518 A MA 43518A MA 43518 B1 MA43518 B1 MA 43518B1
Authority
MA
Morocco
Prior art keywords
azabicyclo
hexanes
serving
substituted
ketohexokinase
Prior art date
Application number
MA43518A
Other languages
English (en)
Other versions
MA43518A (fr
Inventor
Aaron Smith
Kentaro Futatsugi
Kim Huard
Matthew Dowling
Dilinie Fernando
Thomas Victor Magee
Brian Raymer
Andre Shavnya
Benjamin Thuma
Andy Tsai
Meihua Tu
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA43518A publication Critical patent/MA43518A/fr
Publication of MA43518B1 publication Critical patent/MA43518B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)

Abstract

L'invention concerne des 3-azabicyclo[3.1.0]hexanes substitués servant d'inhibiteurs de cétohexokinase, des procédés de fabrication de ces composés ainsi que des procédés comprenant l'administration desdits composés à un mammifère en ayant besoin.
MA43518A 2015-12-29 2016-12-16 3-azabicyclo[3.1.0]hexanes substitués servant d'inhibiteurs de cétohexokinase MA43518B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562272598P 2015-12-29 2015-12-29
US201662423549P 2016-11-17 2016-11-17
PCT/IB2016/057728 WO2017115205A1 (fr) 2015-12-29 2016-12-16 3-azabicyclo[3.1.0]hexanes substitués servant d'inhibiteurs de cétohexokinase

Publications (2)

Publication Number Publication Date
MA43518A MA43518A (fr) 2018-11-07
MA43518B1 true MA43518B1 (fr) 2021-05-31

Family

ID=57755415

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43518A MA43518B1 (fr) 2015-12-29 2016-12-16 3-azabicyclo[3.1.0]hexanes substitués servant d'inhibiteurs de cétohexokinase

Country Status (38)

Country Link
US (6) US9809579B2 (fr)
EP (1) EP3397631B1 (fr)
JP (1) JP6503515B2 (fr)
KR (1) KR102073048B1 (fr)
CN (1) CN108473469B (fr)
AU (1) AU2016380920B2 (fr)
CA (1) CA2952466C (fr)
CL (1) CL2018001667A1 (fr)
CO (1) CO2018006714A2 (fr)
CU (1) CU24540B1 (fr)
CY (1) CY1124389T1 (fr)
DK (1) DK3397631T3 (fr)
EC (1) ECSP18048517A (fr)
ES (1) ES2871251T3 (fr)
GE (2) GEP20207147B (fr)
HR (1) HRP20210769T1 (fr)
HU (1) HUE054380T2 (fr)
IL (1) IL260330B (fr)
LT (1) LT3397631T (fr)
MA (1) MA43518B1 (fr)
MD (1) MD3397631T2 (fr)
MX (1) MX376072B (fr)
NI (1) NI201800072A (fr)
PE (1) PE20181289A1 (fr)
PH (1) PH12018501375A1 (fr)
PL (1) PL3397631T3 (fr)
PT (1) PT3397631T (fr)
RS (1) RS61896B1 (fr)
RU (1) RU2696269C1 (fr)
SG (1) SG11201804363UA (fr)
SI (1) SI3397631T1 (fr)
SV (1) SV2018005709A (fr)
TN (1) TN2018000198A1 (fr)
TW (1) TWI653232B (fr)
UA (1) UA121271C2 (fr)
UY (1) UY37051A (fr)
WO (1) WO2017115205A1 (fr)
ZA (1) ZA201803449B (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2018000198A1 (en) * 2015-12-29 2019-10-04 Pfizer Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
MY199759A (en) 2016-09-02 2023-11-21 Tisento Therapeutics Inc Fused bicyclic sgc stimulators
US10558874B1 (en) 2017-01-19 2020-02-11 State Farm Mutual Automobile Insurance Company Apparatuses, systems and methods for generation and transmission of vehicle operation mode data
CN109316601B (zh) * 2017-07-31 2021-11-09 武汉朗来科技发展有限公司 药物组合物及其用途
TWI707683B (zh) 2018-06-13 2020-10-21 美商輝瑞股份有限公司 Ｇｌｐ－１受體促效劑及其用途
AU2019329884B2 (en) 2018-08-31 2022-01-27 Pfizer Inc. Combinations for treatment of NASH/NAFLD and related diseases
TWI714231B (zh) * 2018-09-04 2020-12-21 美商美國禮來大藥廠 2,6-二胺基吡啶化合物
KR102558308B1 (ko) * 2018-09-27 2023-07-24 주식회사 엘지화학 3-아자바이사이클로[3,1,1]헵탄 유도체 및 이를 포함하는 약제학적 조성물
CN116023365B (zh) * 2019-01-29 2025-02-14 轩竹生物科技股份有限公司 己酮糖激酶抑制剂及其用途
WO2020215034A1 (fr) * 2019-04-19 2020-10-22 The Regents Of The University Of California Axe ampk/caspase-6 contrôlant les lésions hépatiques dans la stéatohépatite non alcoolique
EP4578460A3 (fr) * 2019-05-20 2025-08-27 Pfizer Inc. Combinaisons comprenant du benzodioxol en tant qu'agonistes de glp-1r destinées à être utilisées dans le traitement de la nash/nafld et de maladies associées
CN111978296A (zh) * 2019-05-22 2020-11-24 山东轩竹医药科技有限公司 己酮糖激酶抑制剂及其用途
BR112021024108A2 (pt) 2019-05-31 2022-03-22 Ikena Oncology Inc Inibidores de tead e usos dos mesmos
TW202108559A (zh) 2019-05-31 2021-03-01 美商醫肯納腫瘤學公司 Tead抑制劑及其用途
TWI750685B (zh) * 2019-06-17 2021-12-21 美商美國禮來大藥廠 二取代吡唑化合物
MX2022007105A (es) 2019-12-10 2022-07-11 Pfizer Formas solidas de sal de 1,3-dihidroxi-2-(hidroximetil)propan-2-am ina de acido 2-((4-((s)-2-(5-cloropiridin-2-il)-2-metilbenzo[d][1, 3] dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il) metil)-1h- benzo[d]imidazol-6-carboxilico.
US12534477B2 (en) 2019-12-24 2026-01-27 Hangzhou Zhongmeihuadong Pharmaceutical Co. , Ltd. Compound having KHK inhibitory effect
WO2021129817A1 (fr) * 2019-12-25 2021-07-01 南京明德新药研发有限公司 Composé à base de pyrimidine ayant un effet inhibiteur de la cétohexokinase (chk)
GB202001856D0 (en) * 2020-02-11 2020-03-25 Inorbit Therapeutics Ab Compounds useful in inhibiting ketohexokinase and methods of making and using the same
JP7404553B2 (ja) * 2020-02-13 2023-12-25 イーライ リリー アンド カンパニー ２－［２－メチルアゼチジン－１－イル］－４－フェニル－６－（トリフルオロメチル）－ピリミジン化合物
JP2021134211A (ja) 2020-02-24 2021-09-13 ファイザー・インク Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
CA3176569A1 (fr) 2020-03-27 2021-09-30 Pfizer Inc. Traitement du diabete de type 2 ou de l'obesite ou du surpoids avec de l'acide 2-[(4-{6-[(4-cyano-2-fluorobenzyl) oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl ]-1h-benzimidazole-6-carboxylique ou un sel pharmaceutiquement acceptable correspondant
TWI810550B (zh) * 2020-04-20 2023-08-01 南韓商Ｌｇ化學股份有限公司 3-氮雜二環烷基衍生物及包含其之醫藥組成物
CN111423420A (zh) * 2020-04-30 2020-07-17 广州博济医药生物技术股份有限公司 作为己酮糖激酶抑制剂的并环化合物
CN113754640B (zh) * 2020-06-03 2023-02-14 山东轩竹医药科技有限公司 氘代的己酮糖激酶抑制剂及其用途
EP4190776A4 (fr) * 2020-07-28 2024-02-28 Shandong Xuanzhu Pharma Co., Ltd. Forme de sel et forme cristalline d'un inhibiteur de cétohexokinase et utilisation associée
CN116438200A (zh) 2020-09-10 2023-07-14 普雷西里克斯公司 针对fap的抗体片段
CN114181198B (zh) * 2020-09-15 2025-07-15 山东轩竹医药科技有限公司 嘧啶衍生物类己酮糖激酶抑制剂及其用途
EP4269404A4 (fr) * 2020-12-25 2024-12-04 Xizang Haisco Pharmaceutical Co., Ltd. Inhibiteur de cétohexokinase et son utilisation
EP4313967B1 (fr) 2021-03-29 2025-11-12 Gilead Sciences, Inc. Inhibiteurs de khk
KR20220136939A (ko) 2021-04-01 2022-10-11 주식회사 엘지화학 옥사디아졸 화합물 및 이를 포함하는 약제학적 조성물
WO2022262841A1 (fr) * 2021-06-17 2022-12-22 杭州中美华东制药有限公司 Forme de sel et forme cristalline de composé spiro et son procédé de préparation
AU2022336407A1 (en) 2021-08-31 2024-02-22 Pfizer Inc. Solid forms of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt
WO2023061492A1 (fr) * 2021-10-14 2023-04-20 华领医药技术（上海）有限公司 Dérivé de 2-oxo-3-azabicyclo[3.1.0]hexane
WO2023111817A1 (fr) 2021-12-17 2023-06-22 Pfizer Inc. Formes cristallines d'acide [(1r,5s,6r)-3-{2-[(2s)-2-méthylazetidin-1-yl]-6-(trifluorométhyl) pyrimidin-4-yl}-3-azabicyclo[3.1.0]hex-6-yl]acétique
EP4434982A4 (fr) * 2021-12-24 2025-03-12 LG Chem, Ltd. Dérivé de (s)-2-(2-méthylazétidin-1-yl)pyrimidine et composition pharmaceutique le comprenant
CN114315494B (zh) * 2021-12-29 2023-09-22 苏州楚凯药业有限公司 一种(s)-2-甲基氮杂环丁烷盐酸盐的制备方法
US20250145619A1 (en) * 2022-02-09 2025-05-08 Youngene Therapeutics Co., Ltd Khk inhibitor, preparation method therefor and use thereof
WO2023203135A1 (fr) 2022-04-22 2023-10-26 Precirix N.V. Anticorps radiomarqué amélioré
JP2025517625A (ja) 2022-05-02 2025-06-10 プレシリックス・ナームローゼ・ベンノートシヤープ プレターゲティング
WO2023228023A1 (fr) 2022-05-23 2023-11-30 Pfizer Inc. Traitement du diabète de type 2 ou contrôle de la gestion du poids avec de l'acide 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-méthylbenzo[d][1,3]dioxol-4-yl)pipéridin-1-yl)méthyl)-1-(((s)-oxétan-2-yl)méthyl)-1h-benzo[d]imidazole-6-carboxylique ou un sel pharmaceutique de celui-ci
JP2025535295A (ja) 2022-10-18 2025-10-24 ファイザー・インク パタチン様ホスホリパーゼドメイン含有タンパク質３（ｐｎｐｌａ３）修飾因子
AR132416A1 (es) 2023-04-12 2025-06-25 Centennial Therapeutics Llc Compuestos de pirimidina disustituidos para la inhibición de la cetohexoquinasa
KR20260022334A (ko) 2023-05-31 2026-02-19 센테니얼 테라퓨틱스, 엘엘씨 케토헥소키나제 억제를 위한 이환식 화합물
WO2025099561A1 (fr) 2023-11-07 2025-05-15 Pfizer Inc. Formulations de matrice à libération contrôlée orales d'acide 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}pipéridin-1-yl)méthyl]-1-[(2s)-oxétan-2-ylméthyl]-1h-benzimidazole-6-carboxylique ou d'un sel pharmaceutiquement acceptable de celui-ci
WO2025224648A1 (fr) 2024-04-26 2025-10-30 Pfizer Inc. Compositions/formulations orales de l'acide 2-({4-[(2s)-2-(4-chloro-2-fluorophényl)-2-méthyl-1,3-benzodioxol-4-yl]pipéridin-1-yl}méthyl)-1-[(2s)-oxétan-2-ylméthyl]-1h-benzimidazole-6-carboxylique ou d'un sel pharmaceutiquement acceptable de celui-ci

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980350A (en) 1988-02-25 1990-12-25 Merck & Co., Inc. Piperazinylalkylpyrimidines as hypoglycemic agents
DE4208254A1 (de) 1992-03-14 1993-09-16 Hoechst Ag Substituierte pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel und fungizid
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
ATE416772T1 (de) 1998-07-06 2008-12-15 Bristol Myers Squibb Co Biphenylsulfonamide als zweifach aktive rezeptor antagonisten von angiotensin und endothelin
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
JP4104983B2 (ja) 2001-02-28 2008-06-18 メルク エンド カムパニー インコーポレーテッド メラノコルチン−４受容体作動薬としてのアシル化ピペリジン誘導体
EP1478437B1 (fr) 2002-02-27 2005-08-31 Pfizer Products Inc. Inhibiteurs de l'acetyl-coa-carboxylase
BRPI0510284A (pt) 2004-05-12 2007-10-30 Pfizer Prod Inc derivados de prolina e seu uso como inibidores da dipeptidil peptidase iv
AP2006003768A0 (en) 2004-05-25 2006-10-31 Pfizer Prod Inc TetraazabenzoÄeÜazulene derivatives and analogs tehereof
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
ES2487967T3 (es) 2006-04-20 2014-08-25 Pfizer Products Inc. Compuestos amido heterocíclicos condensados con fenilo para la prevención y el tratamiento de enfermedades mediadas por la glucoquinasa
US8933201B2 (en) 2006-06-07 2015-01-13 The Board Of Regents Of The University Of Oklahoma Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use
WO2008024902A2 (fr) 2006-08-23 2008-02-28 University Of Florida Research Foundation, Inc. Ciblage de fructokinase comme thérapie pour une maladie cardiovasculaire, un syndrome métabolique et une affection rénale
AU2007326950B2 (en) 2006-11-29 2010-10-14 Pfizer Products Inc. Spiroketone acetyl-CoA carboxylase inhibitors
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
EP2209376B1 (fr) 2007-10-11 2013-03-06 GlaxoSmithKline LLC Inhibiteurs inédits de la seh et leur utilisation
WO2009144555A1 (fr) 2008-05-28 2009-12-03 Pfizer Inc. Inhibiteurs de la pyrazolospirocétone acétyl-coa carboxylase
US8318762B2 (en) 2008-05-28 2012-11-27 Pfizer Inc. Pyrazolospiroketone acetyl-CoA carboxylase inhibitors
US20110130365A1 (en) 2008-07-29 2011-06-02 Benbow John W Fluorinated Heteroaryls
US20120108565A1 (en) * 2008-07-30 2012-05-03 Lalima Sharma Pyrrole carboxylic acid derivatives as antibacterial agents
AP2728A (en) 2008-08-28 2013-08-31 Pfizer Dioxa-bicyclo[3.2.1.] octane-2,3,4-triol derivatives
WO2010086820A1 (fr) 2009-02-02 2010-08-05 Pfizer Inc. Dérivés de 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazépin-6(5h)-yl)phényle
CA2754685A1 (fr) 2009-03-11 2010-09-16 Pfizer Inc. Indazole amides substitues
DK2406253T3 (da) 2009-03-11 2013-08-12 Pfizer Benzofuranylderivater anvendt som glucokinase-inhibitorer
EP2408780A2 (fr) 2009-03-20 2012-01-25 Pfizer Inc. 3-oxa-7-azabicycloý3,3.1¨nonanes
CA2756542C (fr) 2009-04-08 2017-08-22 Actelion Pharmaceuticals Ltd 6-(3-azabicyclo[3.1.0]hex-3-yl)-2-phenylpyrimidines
US20120052130A1 (en) 2009-05-08 2012-03-01 Pfizer Inc. Gpr 119 modulators
CA2759843A1 (fr) 2009-05-08 2010-11-10 Pfizer Inc. Modulateurs de gpr119
AP2799A (en) 2009-06-05 2013-11-30 Pfizer 1-(Piperidin-4-YL)-pyrazole derivatives as GPR 119modulators
WO2011005611A1 (fr) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Agonistes du récepteur de la neuromédine u et leurs utilisations
KR101686913B1 (ko) 2009-08-13 2016-12-16 삼성전자주식회사 전자기기에서 이벤트 서비스 제공 방법 및 장치
EP2560962B1 (fr) * 2010-04-22 2015-05-20 Janssen Pharmaceutica NV Composés indazole en tant qu' inhibiteurs de kétohéxokinase
EP2600897A2 (fr) * 2010-08-06 2013-06-12 The Regents of the University of Colorado, A Body Corporate Procédés et compositions destinés à l'inhibition de la fructokinase
CN102432598A (zh) * 2010-09-29 2012-05-02 江苏恒瑞医药股份有限公司 三环化合物、其制备方法及其在医药上的应用
US9371282B2 (en) 2013-05-17 2016-06-21 Centrexion Therapeutics Corporation Somatostatin receptor subtype 4 (SSTR4) agonists
KR102592370B1 (ko) 2014-02-11 2023-10-25 알닐람 파마슈티칼스 인코포레이티드 케토헥소키나제(ＫＨＫ) ｉＲＮＡ 조성물 및 그의 사용 방법
TN2018000198A1 (en) * 2015-12-29 2019-10-04 Pfizer Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors

Also Published As

Publication number Publication date
JP2019500383A (ja) 2019-01-10
IL260330A (en) 2018-08-30
CO2018006714A2 (es) 2018-07-10
SG11201804363UA (en) 2018-07-30
GEP20207147B (en) 2020-09-10
RS61896B1 (sr) 2021-06-30
US20200377482A1 (en) 2020-12-03
PH12018501375A1 (en) 2019-02-11
US20180037575A1 (en) 2018-02-08
US10988463B2 (en) 2021-04-27
HK1259073A1 (zh) 2019-11-22
TW201726659A (zh) 2017-08-01
HUE054380T2 (hu) 2021-09-28
ECSP18048517A (es) 2018-07-31
AU2016380920B2 (en) 2019-10-31
US10787438B2 (en) 2020-09-29
AU2016380920A1 (en) 2018-06-14
PT3397631T (pt) 2021-05-28
US10174007B2 (en) 2019-01-08
CN108473469B (zh) 2020-11-03
US20200148669A1 (en) 2020-05-14
US20170183328A1 (en) 2017-06-29
ES2871251T3 (es) 2021-10-28
IL260330B (en) 2021-07-29
US9809579B2 (en) 2017-11-07
RU2696269C1 (ru) 2019-08-01
DK3397631T3 (da) 2021-05-25
CA2952466C (fr) 2025-07-08
LT3397631T (lt) 2021-06-10
BR112018012047A2 (pt) 2018-12-04
PE20181289A1 (es) 2018-08-07
NI201800072A (es) 2018-11-22
UY37051A (es) 2017-07-31
US20190106412A1 (en) 2019-04-11
CY1124389T1 (el) 2022-07-22
TWI653232B (zh) 2019-03-11
MD3397631T2 (ro) 2021-08-31
CL2018001667A1 (es) 2018-08-03
HRP20210769T1 (hr) 2021-06-25
EP3397631A1 (fr) 2018-11-07
UA121271C2 (uk) 2020-04-27
JP6503515B2 (ja) 2019-04-17
US20210309644A1 (en) 2021-10-07
CU20180046A7 (es) 2018-09-05
CN108473469A (zh) 2018-08-31
CA2952466A1 (fr) 2017-06-29
MA43518A (fr) 2018-11-07
KR20180083427A (ko) 2018-07-20
EP3397631B1 (fr) 2021-04-07
MX2018007755A (es) 2018-11-09
SV2018005709A (es) 2018-09-10
KR102073048B1 (ko) 2020-02-04
SI3397631T1 (sl) 2022-01-31
GEAP202014820A (en) 2020-03-10
ZA201803449B (en) 2019-02-27
PL3397631T3 (pl) 2021-09-20
WO2017115205A1 (fr) 2017-07-06
TN2018000198A1 (en) 2019-10-04
MX376072B (es) 2025-03-07
CU24540B1 (es) 2021-08-06
US11634410B2 (en) 2023-04-25

Similar Documents

Publication Publication Date Title
MA43518A (fr) 3-azabicyclo[3.1.0]hexanes substitués servant d'inhibiteurs de cétohexokinase
CL2020001048A1 (es) Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281)
MA38959A1 (fr) Modulateurs du facteur b du complément
CL2018002291A1 (es) Anticuerpos anti-fgfr2iiib afucosilados (divisional solicitud 201600221)
WO2015168635A3 (fr) Compositions et procédés pour moduler l'expression du facteur b du complément
MX2022005380A (es) Composiciones que comprenden colina.
UY36275A (es) Compuestos aminopirimidinilo
MX381417B (es) Inhibidores de glucosidasa.
MA40576A (fr) Anticorps et immunoconjugués anti-her2
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
UA120058C2 (uk) Пестицидні композиції
EA201790627A1 (ru) СТИМУЛЯТОРЫ рГЦ
MA39152B1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
MX2022006817A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
BR112014026160A2 (pt) métodos para tratar intolerância à lactose
WO2016057683A3 (fr) Nouveaux anticorps anti-nodaux et méthodes d'utilisation de ceux-ci
EA201890186A1 (ru) Применение штаммов микробактерий для получения антибактериальных агентов
MA38816B1 (fr) Sulfamidase modifiée et sa production
JO3742B1 (ar) مركب بيرانو داي بيريدين
BR112017002675A2 (pt) métodos para aperfeiçoar desempenho miocárdico em pacientes de fontan com o uso de composições de udenafila
WO2015109318A3 (fr) Méthodes thérapeutiques
EA201892235A1 (ru) Гранулированная композиция для перорального применения
MX2016013439A (es) Formas solidas de un compuesto farmaceuticamente activo.
SA519410561B1 (ar) عوامل صيدلية، تركيبات، وطرق تتعلق بذلك
RU2016108801A (ru) Пептид, обладающий лечебным действием против болезни Альцгеймера